孟鲁司特钠联合布地奈德治疗哮喘的疗效分析

Efficacy analysis of montelukast sodium combined with budesonide in the treatment of asthma

目的分析孟鲁司特钠联合布地奈德治疗哮喘的临床疗效。方法 150例哮喘患者,采用随机数字表法分为对照组和观察组,各75例。对照组患者采用布地奈德进行治疗,观察组采用孟鲁司特钠联合布地奈德进行治疗。比较两组患者的临床疗效、肺功能指标、症状改善时间、哮喘控制情况及不良反应发生情况。结果治疗前,两组第1秒用力呼气容积占预计值的百分比(FEV1%)、第1秒用力呼气容积与用力肺活量比值(FEV1/FVC)、呼吸气流速峰值占预计值的百分比(PEF%)水平对比差异无统计学意义(P>0.05);治疗后,观察组FEV1%、FEV1/FVC及PEF%水平均高于对照组,差异有统计学意义(P<0.05)。观察组总有效率为93.3%(70/75),高于对照组的81.3%(61/75),差异具有统计学意义(P<0.05)。观察组呼吸困难消失时间为(3.45±0.51)d,哮鸣音消失时间为(4.30±0.75)d,喘息消失时间为(2.55±0.32)d,均短于对照组的(6.30±0.87)、(6.73±1.22)、(4.13±0.54)d,差异有统计学意义(P<0.05)。治疗前,两组哮喘控制测试表(ACT)评分对比差异无统计学意义(P>0.05);治疗后,观察组ACT评分高于对照组,差异具有统计学意义(P<0.05)。结论采用孟鲁司特钠联合布地奈德治疗哮喘疗效显著,可有效改善肺功能,在较短时间内恢复临床症状及体征,且安全性高,具有临床推广价值。

Objective To analyze the clinical efficacy of montelukast sodium combined with budesonide in the treatment of asthma.Methods A total of 150 asthma patients were divided into control group and observation group according to random numerical table,with 75 cases in each group.The control group was treated with budesonide,and the observation group was treated with montelukast sodium combined with budesonide.The clinical efficacy,pulmonary indicators,symptoms improvement time,asthma control status and occurrence of adverse reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference in forced expiratory volume in the first second as a percentage of the predicted value(FEV1%),FEV1/forced vital capacity(FEV1/FVC)and peak expiratory flow as a percentage of the predicted value(PEF%)between the two groups(P>0.05).After treatment,the FEV1%,FEV1/FVC and PEF%of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).The total effective rate of the observation group was 93.3%(70/75),which was higher than 81.3%(61/75)of the control group,and the difference was statistically significant(P<0.05).The disappearance time of dyspnea(3.45±0.51)d,disappearance time of wheezing(4.30±0.75)d and disappearance time of asthma(2.55±0.32)d of the observation group were shorter than(6.30±0.87),(6.73±1.22)and(4.13±0.54)d of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in asthma control test(ACT)score between the two groups(P>0.05).After treatment,the ACT score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of montelukast sodium and budesonide shows remarkable efficacy on asthma,which can effectively improve pulmonary function,restore clinical symptoms and signs in a short time with high safety.It contains clinical promotion value.